These results together indicate that α-SMA+ CAFs had an impact on the recruitment of both tumor-promoting and anti-tumor immune cells, and a thorough knowledge of this internal interaction could help identify a crucial target for the treatment of ESCC. The gene discussed is ACTA1; the disease is neoplasm.